Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

ClinicalTrials.gov ID: NCT05600777

Public ClinicalTrials.gov record NCT05600777. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 27, 2026, 2:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2)

Study identification

NCT ID
NCT05600777
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Enrollment
975 participants

Conditions and interventions

Interventions

  • BLU-5937 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 4, 2022
Primary completion
Jun 10, 2026
Completion
Mar 16, 2027
Last update posted
Apr 14, 2026

2022 – 2027

United States locations

U.S. sites
56
U.S. states
28
U.S. cities
52
Facility City State ZIP Site status
GSK Investigational Site Foley Alabama 36535
GSK Investigational Site Litchfield Park Arizona 85340
GSK Investigational Site Phoenix Arizona 85032
GSK Investigational Site Los Angeles California 90025
GSK Investigational Site Los Angeles California 90048
GSK Investigational Site Paramount California 90723
GSK Investigational Site Redding California 96001
GSK Investigational Site Sacramento California 95661
GSK Investigational Site San Diego California 92108
GSK Investigational Site San Diego California 92120
GSK Investigational Site San Jose California 95117
GSK Investigational Site Aurora Colorado 80012
GSK Investigational Site Colorado Springs Colorado 80923
GSK Investigational Site Denver Colorado 80230
GSK Investigational Site Washington D.C. District of Columbia 20007
GSK Investigational Site Daytona Beach Florida 32117
GSK Investigational Site Fort Lauderdale Florida 33324
GSK Investigational Site Jacksonville Florida 32224
GSK Investigational Site Leesburg Florida 34748
GSK Investigational Site Orlando Florida 32713
GSK Investigational Site Santa Rosa Beach Florida 32459
GSK Investigational Site Sarasota Florida 34239
GSK Investigational Site Sweetwater Florida 33172
GSK Investigational Site Cumming Georgia 30041
GSK Investigational Site Chicago Illinois 60612
GSK Investigational Site River Forest Illinois 60305
GSK Investigational Site West Des Moines Iowa 50266
GSK Investigational Site Lexington Kentucky 40509
GSK Investigational Site Chevy Chase Maryland 20815
GSK Investigational Site Methuen Massachusetts 03801
GSK Investigational Site North Dartmouth Massachusetts 02747
GSK Investigational Site Ypsilanti Michigan 48197
GSK Investigational Site Edina Minnesota 55435
GSK Investigational Site Rochester Minnesota 55905
GSK Investigational Site Woodbury Minnesota 55125
GSK Investigational Site St Louis Missouri 63141
GSK Investigational Site Missoula Montana 59808
GSK Investigational Site Omaha Nebraska 68124
GSK Investigational Site Charlotte North Carolina 28211
GSK Investigational Site Gastonia North Carolina 28054
GSK Investigational Site Winston-Salem North Carolina 27103
GSK Investigational Site Columbus Ohio 43235
GSK Investigational Site Tulsa Oklahoma 74136
GSK Investigational Site Portland Oregon 97213
GSK Investigational Site Danville Pennsylvania 17822
GSK Investigational Site Philadelphia Pennsylvania 19107
GSK Investigational Site Warwick Rhode Island 02886
GSK Investigational Site Anderson South Carolina 29621
GSK Investigational Site Charleston South Carolina 29406
GSK Investigational Site Charleston South Carolina 29412
GSK Investigational Site Franklin Tennessee 37067
GSK Investigational Site Dallas Texas 75231-4307
GSK Investigational Site San Antonio Texas 78207
GSK Investigational Site San Antonio Texas 78258
GSK Investigational Site Norfolk Virginia 23507
GSK Investigational Site Bellingham Washington 98225

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 196 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05600777, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 14, 2026 · Synced Jun 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05600777 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →